ReviR Therapeutics Secures $30M in Series A Funding for AI-Driven Drug Discovery
ReviR Therapeutics integrates artificial intelligence with biopharmaceutical development to create targeted therapies for serious genetic diseases.
Company Name: ReviR Therapeutics
Location: Brisbane, CA
Sector: Biotechnology, AI Drug Discovery
Funding Details: Closed $30 million in Series A financing, bringing the total raised to $54 million. The round was led by Lapam Capital, with contributions from CDH Investments, 5Y Capital, Yael Capital, XtalPi, and the Charcot-Marie Tooth Research Foundation (CMTRF).
Purpose of Investment: To enhance its AI-driven drug discovery platform, VoyageR, and support the clinical development of treatments for neurogenetic diseases such as Huntington’s disease, Charcot-Marie-Tooth disease, and ALS.
Leadership: Led by Dr. Peng Yue, CEO.
Product and Innovation: ReviR Therapeutics is pioneering the development of RNA-targeting small molecule therapies. The company’s innovative approach focuses on modulating the causal genes of diseases, utilizing its proprietary SpliceR modulation technology aimed at RNA targets to develop disease-modifying therapies. These therapies are designed to be highly specific, efficacious, and safe.
Company Growth: With a robust pipeline focused on CNS diseases, cancer, and rare genetic disorders, ReviR Therapeutics is advancing towards clinical development with a focus on addressing genetic diseases with limited or no current treatment options.
Global Impact: The company's efforts are poised to make significant advancements in the treatment of debilitating neurogenetic disorders, improving the quality of life for patients worldwide and filling a critical gap in medical care.
About the Company: ReviR Therapeutics integrates artificial intelligence with biopharmaceutical development to create targeted therapies for serious genetic diseases.